Contributors. Preface. 1. Development of allogeneic hematopoietic stem cell transplantation (HSCT); J. Castro, E.D. Ball. 2. Immunosuppression with limited toxicity: characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation; A. Bashey. 3. Mobilization of allogeneic peripheral blood progenitor cells; P. Law, T. Lane. 4. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies; M. Sykes, T. Spitzer. 5. Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer; A.M. Carella, E. Lerma, M. Cavaliere, M.T. Corsetti. 6. Non-myeloablative hematopoietic stem cell transplantation (NHT) in the treatment of human malignancies: from animal models to clinical practice; A. Shimoni, A. Nagler. 7. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy; I. Khouri, S. Giralt, R. Champlin. 8. Outpatient allografting in hematologic malignancies and nonmalignant disorders - applying lessons learned in the canine model to humans; M. Maris, R.F. Storb. 9. Non-myeloablative transplants for congenital diseases; J. Donahue, E. Carrier. Index.
Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.
Springer Book Archives